Psychotic disorders Mental and Behavioural Disorders
Conditions
Interventions
The intervention is Therapeutic Drug Monitoring with rapid results feedback and a clinician guidance algorithm.
Sponsors
King's College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. People admitted to participating inpatient wards or those under the care of an outpatient clinical service 2. People for whom the treating clinician has identified a need for antipsychotic dose review within routine clinical care 3. Age 18-65 years 4. Current diagnosis from one of the diagnostic categories of ICD-10: F20-F29 5. Regularly prescribed oral olanzapine or risperidone as monotherapy for the treatment of psychotic symptoms 6. Legally detained participants will be included if they have capacity to consent to the study
Exclusion criteria
Exclusion criteria: 1. Current diagnosis of drug induced psychosis (ICD-10 F10-19) 2. Use of clozapine in past 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of participants whose drug plasma level is within target therapeutic range at follow-up (between 4 and 8 weeks after participation in the trial) | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of participants whose plasma drug level, at follow-up (between 4 and 8 weeks after participation in the trial), falls within the range above or below the target therapeutic range. The acceptability of these suboptimal plasma level ranges will be assessed with regards to tolerance and clinical response. Tolerance will be measured using the side effect rating scales and response using the Positive and Negative Syndrome Scale at follow-up. | — |
Countries
United Kingdom
Outcome results
None listed